Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004;15:475–95. https://doi.org/10.1046/j.1540-8167.2004.03534.x.
Article PubMed PubMed Central Google Scholar
Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121:1047–60. https://doi.org/10.1161/circulationaha.109.192704.
Article PubMed PubMed Central Google Scholar
Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and Torsades de Pointes. J Am Coll Cardiol. 2016;67:1639–50. https://doi.org/10.1016/j.jacc.2015.12.063.
2022. https://www.crediblemeds.org. Accessed 29 Jul 2022.
Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39:16–25. https://doi.org/10.1007/s11096-016-0414-2.
2022. https://www.hey.nhs.uk/wp/wp-content/uploads/2016/03/formularyDrugsAdministeredPrimaryCareECGMonitoring.pdf. Accessed 29 Jul 2022.
Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs RJ. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479–87. https://doi.org/10.1161/circoutcomes.113.000152.
Article PubMed PubMed Central Google Scholar
Vandael E, Vandenberk B, Vandenberghe J, Van den Bosch B, Willems R, Foulon V. A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model. Br J Clin Pharmacol. 2018;84:2824–35. https://doi.org/10.1111/bcp.13740.
Article PubMed PubMed Central Google Scholar
Warnier MJ, Rutten FH, Souverein PC, de Boer A, Hoes AW, De Bruin ML. Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol. Pharmacoepidemiol Drug Saf. 2015;24:701–8. https://doi.org/10.1002/pds.3792.
CAS Article PubMed Google Scholar
Sharma S, Martijn Bos J, Tarrell RF, Simon GJ, Morlan BW, Ackerman MJ, Caraballo PJ. Providers’ response to clinical decision support for QT prolonging drugs. J Med Syst. 2017;41:161. https://doi.org/10.1007/s10916-017-0803-7.
Pezo RC, Yan AT, Earle C, Chan KK. Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. Heart. 2019;105:1649–55. https://doi.org/10.1136/heartjnl-2018-314674.
CAS Article PubMed Google Scholar
Trinkley KE, Pell JM, Martinez DD, Maude NR, Hale G, Rosenberg MA. Assessing prescriber behavior with a clinical decision support tool to prevent drug-induced long QT syndrome. Appl Clin Inform. 2021;12:190–7. https://doi.org/10.1055/s-0041-1724043.
Article PubMed PubMed Central Google Scholar
Good MM, Riad FS, Good CB, Shalaby AA. Provider response to QTc prolongation on standard 12-lead EKG: Do we notice or do we care? Pacing Clin Electrophysiol. 2016;39:1174–80. https://doi.org/10.1111/pace.12951.
Putnikovic M, Jordan Z, Munn Z, Borg C, Ward M. Use of electrocardiogram monitoring in adult patients taking high-risk QT interval prolonging medicines in clinical practice: systematic review and meta-analysis. Drug Saf. 2022. https://doi.org/10.1007/s40264-022-01215-x.
Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788–90.
Salem M, Reichlin T, Fasel D, Leuppi-Taegtmeyer A. Torsade de pointes and systemic azole antifungal agents: analysis of global spontaneous safety reports. Glob Cardiol Sci Pract. 2017;2017:11. https://doi.org/10.21542/gcsp.2017.11.
CAS Article PubMed PubMed Central Google Scholar
Benjamin LN, Elshafey S, Kistler EA, Oseran A, Rutledge SM, Smith ID, Theodore M, Venn RA, Stern TA. Recommendations for QTc monitoring: rational or arbitrary? Prim Care Companion CNS Disord. 2018;20:18f02327. https://doi.org/10.4088/PCC.18f02327.
Facchini M, Sala L, Malfatto G, Bragato R, Redaelli G, Invitti C. Low-K+ dependent QT prolongation and risk for ventricular arrhythmia in anorexia nervosa. Int J Cardiol. 2006;106:170–6. https://doi.org/10.1016/j.ijcard.2005.01.041.
Genovesi S, Nava E, Bartolucci C, Severi S, Vincenti A, Contaldo G, Bigatti G, Ciurlino D, Bertoli SV. Acute effect of a peritoneal dialysis exchange on electrolyte concentration and QT interval in uraemic patients. Clin Exp Nephrol. 2019;23:1315–22. https://doi.org/10.1007/s10157-019-01773-y.
CAS Article PubMed Google Scholar
Drew D, Baranchuk A, Hopman W, Brison RJ. The impact of fever on corrected QT interval. J Electrocardiol. 2017;50:570–5. https://doi.org/10.1016/j.jelectrocard.2017.04.006.
Capparelli FJ, Abello M, Patricio Maskin L, Arista E, Hlavnicka A, Diaz MF, Varela D, Wainsztein NA. QTc prolongation after brain surgery. Neurol Res. 2013;35:159–62. https://doi.org/10.1179/1743132813Y.0000000169.
CAS Article PubMed Google Scholar
Lee YS, Choi JW, Bae EJ, Park WI, Lee HJ, Oh PS. The corrected QT (QTc) prolongation in hyperthyroidism and the association of thyroid hormone with the QTc interval. Korean J Pediatr. 2015;58:263–6. https://doi.org/10.3345/kjp.2015.58.7.263.
Article PubMed PubMed Central Google Scholar
Kligfield P, Badilini F, Denjoy I, Babaeizadeh S, Clark E, De Bie J, Devine B, Extramiana F, Generali G, Gregg R, Helfenbein E, Kors J, Leber R, Macfarlane P, Maison-Blanche P, Rowlandson I, Schmid R, Vaglio M, van Herpen G, Xue J, Young B, Green CL. Comparison of automated interval measurements by widely used algorithms in digital electrocardiographs. Am Heart J. 2018;200:1–10. https://doi.org/10.1016/j.ahj.2018.02.014.
Hnatkova K, Gang Y, Batchvarov VN, Malik M. Precision of QT interval measurement by advanced electrocardiographic equipment. Pacing Clin Electrophysiol. 2006;29:1277–84. https://doi.org/10.1111/j.1540-8159.2006.00532.x.
Hnatkova K, Malik M. Sources of QTc variability: implications for effective ECG monitoring in clinical practice. Ann Noninvasive Electrocardiol. 2020;25: e12730. https://doi.org/10.1111/anec.12730.
Malik M, Färbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002;87:220–8. https://doi.org/10.1136/heart.87.3.220.
CAS Article PubMed PubMed Central Google Scholar
Hnatkova K, Vicente J, Johannesen L, Garnett C, Stockbridge N, Malik M. Errors of fixed QT heart rate corrections used in the assessment of drug-induced QTc changes. Front Physiol. 2019;10:635. https://doi.org/10.3389/fphys.2019.00635.
Article PubMed PubMed Central Google Scholar
Garnett CE, Zhu H, Malik M, Fossa AA, Zhang J, Badilini F, Li J, Darpö B, Sager P, Rodriguez I. Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am Heart J. 2012;163:912–30. https://doi.org/10.1016/j.ahj.2012.02.023.
Malik M, Johannesen L, Hnatkova K, Stockbridge N. Universal correction for QT/RR hysteresis. Drug Saf. 2016;39:577–88. https://doi.org/10.1007/s40264-016-0406-0.
Malik M, Garnett CE, Zhang J. Thorough QT studies: questions and quandaries. Drug Saf. 2010;33:1–14. https://doi.org/10.2165/11319160-000000000-00000.
Guzik P, Malik M. ECG by mobile technologies. J Electrocardiol. 2016;49:894–901. https://doi.org/10.1016/j.jelectrocard.2016.07.030.
留言 (0)